USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
TROPHOGEN, INC.
Address:
9714 Medical Center Dr.
ROCKVILLE, MD
Phone:
N/A
URL:
N/A
EIN:
152232768
DUNS:
63841477
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,222,304.00 6
SBIR Phase II $7,663,068.00 4

Award List:

Development of Superactive Analogs of LH and FSH

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Our previous structure-function studies resulted in the development of the first analogs of glycoprotein hormones with major increases in receptor binding affinity and bioactivity ("super active analogs"). More recently, we have further optimized human… More

Development of Novel VEGF Analogs

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$108,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Our previous structure-function studies resulted in the development of the first analogs of glycoprotein hormones with major increases in receptor binding and bioactivity ("super-active analogs"). The majority of cancers are highly dependent on vascular… More

Development of Superactive Analogs of FSH

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$1,217,268.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Infertility affects about 10% of American couples, and there is a very large and rapidly growing market for therapeutics in this field, particularly the primary hormone responsible for ovarian oocyte development, follicle-stimulating hormone (FSH). Although… More

Development of Superagonist Analogs of Recombinant Human TSH

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$101,500.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Thyroid cancer is the most common malignancy of endocrine tissues and most patients require lifelong surveillance with diagnostic thyroid-stimulating hormone (TSH)-stimulated radioiodine uptake as well as remnant or metastatic ablation with radioidine therapy.… More

Recombinant Human TSH Superagonists for Imaging of Thyroid Cancer

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$478,846.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Thyroid cancer is the most common malignancy of endocrine tissues and most patients require lifelong surveillance with diagnostic thyroid-stimulating hormone (TSH)- stimulated radio-iodine imaging as well as remnant or metastatic ablation with radioiodine… More

Development of Superagonist Analogs of Recombinant Human TSH for Imaging and Ther

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$1,774,735.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Thyroid cancer is increasingly prevalent and the most common malignancy of endocrine tissues, and most patients require lifelong surveillance with diagnostic thyroid-stimulating hormone (TSH)-stimulated radioiodine upta ke as well as thyroid remnant or tumor… More

Recombinant Human TSH Superagonists for Imaging of Thyroid Cancer

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$1,739,909.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Thyroid cancer is increasingly prevalent and the most common malignancy of endocrine tissues, and most patients require lifelong surveillance with diagnostic thyroid-stimulating hormone (TSH)-stimulated radioiodine upta ke as well as thyroid remnant or tumor… More

Development of Superactive Analogs of FSH for Human Infertility

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$2,931,156.00
Agency:
HHS
Principal Investigator:
Bruce D. Weintraub – 301-838-1936
Abstract:
DESCRIPTION (provided by applicant): Infertility affects about 10% of American couples, and there is a very large and rapidly growing market for therapeutics in this field, particularly the primary hormone responsible for ovarian oocyte development, human(h) follicle-stimulating hormone (FSH).… More

Novel High Affinity and Long-Acting Bovine FSH Analogs for Veterinary Superovulat

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$150,000.00
Agency:
HHS
Principal Investigator:
Bruce D. Weintraub – 301-838-1936
Abstract:
DESCRIPTION (provided by applicant): Bovine ovarian superovulation is the current state-of-the-art method employed worldwide to maintain and improve milk and beef production through genetic selection of the best quality breeders and best quality embryos for transfer. These embryos may either be… More

Novel High Affinity VEGF Analogs for Imaging Thyroid Cancer

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$283,958.00
Agency:
HHS
Principal Investigator:
Bruce D. Weintraub – (301) 838-1936
Abstract:
DESCRIPTION (provided by applicant): Thyroid cancer of follicular origin is the most common malignancy of endocrine tissues, disproportionally affecting women, and is one of the few cancers greatly increasing in incidence and prevalence for unknown reasonsnot solely attributable to improved… More